東陽光藥(01558.HK)盈警:預計年度歸母淨虧(考慮可轉債)5.46億至6.3億元
格隆匯3月11日丨東陽光藥(01558.HK)發佈公吿,截至2021年12月31日止年度,集團預期錄得歸母淨虧損(考慮可轉換債券)約為人民幣5.46億元至約人民幣6.30億元,而上年度則錄得歸母淨利潤(考慮可轉換債券)約人民幣8.39億元(跌幅約為165%至175%)。該年度集團預期錄得歸母淨虧損(不考慮可轉換債券)約人民幣3.84億元至約人民幣4.43億元,而上年度則錄得歸母淨利潤(不考慮可轉換債券)約人民幣5.90億元(跌幅約為165%至175%)。
公吿稱,預期減少主要由於1.新冠疫情初期疊加流感高峯季,終端醫院機構對公司核心產品可威備貨需求較高,因此公司在疫情初期有較多可威發貨;2.新冠疫情爆發後,國內疫情防控嚴峻,導致終端醫療機構患者人流急速下降,終端處方量隨之下降,且由於疫情期間,人們防護意識加強、社交頻率驟降等原因,導致可威渠道庫存消耗速度較低;3.由於疫情前期可威發貨數量較多,以及疫情爆發後,終端可威處方量需求降低,導致可威於去年處於去庫存階段,故導致公司2021年全年業績相較於2020年出現較大幅度下滑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.